Cargando…

What's new in critical illness and injury science? An evidence-based analysis of the impact of Janus Kinase inhibitors on 28-day mortality in patients admitted with COVID-19

Detalles Bibliográficos
Autores principales:	Miller, Andrew C., D'Silva, Yannick A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547681/ https://www.ncbi.nlm.nih.gov/pubmed/34760655 http://dx.doi.org/10.4103/ijciis.ijciis_80_21

Ejemplares similares

What's New in Critical Illness and Injury Science? Mortality effects of tocilizumab for patients admitted with COVID-19 pneumonia
por: Miller, Andrew C., et al.
Publicado: (2021)

High 28-day mortality in critically ill patients with sepsis and concomitant active cancer
por: Wang, Yong-gang, et al.
Publicado: (2018)

Albumin–Globulin Ratio Is an Independent Determinant of 28-Day Mortality in Patients with Critical Illness
por: Liu, Bin, et al.
Publicado: (2021)

Itch and Janus Kinase Inhibitors
por: HAN, Yujin, et al.
Publicado: (2023)

Brainstem response patterns in deeply-sedated critically-ill patients predict 28-day mortality
por: Rohaut, Benjamin, et al.
Publicado: (2017)

Gut bacteriobiota and mycobiota are both associated with Day-28 mortality among critically ill patients
por: Prevel, Renaud, et al.
Publicado: (2022)

What’s New in Critical Illness and Injury Science? Delirium, COVID-19, and critical illness
por: Miller, Andrew C.
Publicado: (2022)

The association between nutritional adequacy and 28-day mortality in the critically ill is not modified by their baseline nutritional status and disease severity
por: Lew, Charles Chin Han, et al.
Publicado: (2019)

Janus kinase inhibitors: jackpot or potluck?
por: Pavithran, Keechilat, et al.
Publicado: (2012)

Janus Kinase Inhibitors and Cell Therapy
por: Assal, Amer, et al.
Publicado: (2021)

Whats new in critical illness and injury science: Predicting mortality in trauma!
por: Singh, Ajai
Publicado: (2015)

A simple APACHE IV risk dynamic nomogram that incorporates early admitted lactate for the initial assessment of 28-day mortality in critically ill patients with acute myocardial infarction
por: Song, Jikai, et al.
Publicado: (2022)

Association between Malnutrition and 28-Day Mortality and Intensive Care Length-of-Stay in the Critically ill: A Prospective Cohort Study
por: Lew, Charles Chin Han, et al.
Publicado: (2017)

Effects of time and day of admission on the outcome of critically ill patients admitted to ICU
por: Orsini, Jose, et al.
Publicado: (2016)

Association between incident delirium and 28- and 90-day mortality in critically ill adults: a secondary analysis
por: Duprey, Matthew S., et al.
Publicado: (2020)

Using machine learning algorithms to predict 28-day mortality in critically ill elderly patients with colorectal cancer
por: Guo, Chunxia, et al.
Publicado: (2023)

The Impact of CoronaVac Vaccination on 28-day Mortality Rate of Critically Ill Patients with COVID-19 in Türkiye
por: Gül, Fethi, et al.
Publicado: (2023)

Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
por: BALLANGER, Fabienne, et al.
Publicado: (2023)

What's new in critical illness and injury science? Intravenous immunoglobulin for COVID-19 with severe or critical illness
por: Miller, Andrew C., et al.
Publicado: (2020)

The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis
por: Veale, Douglas J, et al.
Publicado: (2019)

Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)

Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)

Janus kinase inhibitors for the therapy of atopic dermatitis
por: Traidl, Stephan, et al.
Publicado: (2021)

Role of Janus Kinase Inhibitors in Therapy of Psoriasis
por: Słuczanowska-Głąbowska, Sylwia, et al.
Publicado: (2021)

Janus kinase inhibitors in autoimmune bullous diseases
por: Huang, Dawei, et al.
Publicado: (2023)

Clinical Characteristics and Predictors of 28-Day Mortality in 352 Critically Ill Patients with COVID-19: A Retrospective Study
por: Alharthy, Abdulrahman, et al.
Publicado: (2021)

Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors
por: Knight, Emily A., et al.
Publicado: (2015)

The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
por: De Vries, L.C.S., et al.
Publicado: (2017)

Role of janus kinase inhibitors in the treatment of alopecia areata
por: Triyangkulsri, Korn, et al.
Publicado: (2018)

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
por: Qi, Fei, et al.
Publicado: (2021)

Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib
por: Nash, David, et al.
Publicado: (2022)

Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
por: Núñez, Paulina, et al.
Publicado: (2023)

What's new in critical illness and injury science? Convalescent plasma for coronavirus disease-2019 patients with severe or critical illness
por: Miller, Andrew Carl, et al.
Publicado: (2021)

Red Blood Cell Distribution Width as a Predictor of 28‐Day Mortality in Critically Ill Patients With Alcohol Use Disorder
por: Liao, Lin, et al.
Publicado: (2020)

Clinical characteristics and risk factors for 28-day mortality in critically ill patients with COVID-19: a retrospective cohort study
por: YAKAR, Mehmet Nuri, et al.
Publicado: (2021)

Prediction of 28-day mortality in critically ill patients with COVID-19: Development and internal validation of a clinical prediction model
por: Leoni, Matteo Luigi Giuseppe, et al.
Publicado: (2021)

Performance of NUTRIC score to predict 28-day mortality in critically ill patients after replacing APACHE II with SAPS 3
por: Souza, Ivens Augusto Oliveira, et al.
Publicado: (2022)

Early glycaemic variability increases 28-day mortality and prolongs intensive care unit stay in critically ill patients with pneumonia
por: Kim, Seong Ho, et al.
Publicado: (2022)

Association between early nutrition support and 28-day mortality in critically ill patients: the FRANS prospective nutrition cohort study
por: Pardo, Emmanuel, et al.
Publicado: (2023)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_cf3likf3d8mr2p67om4oebce62